Olodaterol
- Generic Name
- Olodaterol
- Brand Names
- Inspiolto Respimat, Stiolto, Striverdi Respimat
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26N2O5
- CAS Number
- 868049-49-4
- Unique Ingredient Identifier
- VD2YSN1AFD
- Background
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel i...
- Indication
Olodaterol is indicated for use in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma.
- Associated Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- -
Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2013-10-25
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 229
- Registration Number
- NCT01969721
- Locations
- 🇨🇿
1237.11.42004 Boehringer Ingelheim Investigational Site, Rokycany, Czech Republic
🇩🇪1237.11.49003 Boehringer Ingelheim Investigational Site, Großhansdorf, Germany
🇩🇪1237.11.49005 Boehringer Ingelheim Investigational Site, Hamburg, Germany
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
- Conditions
- Interventions
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 813
- Registration Number
- NCT01964352
- Locations
- 🇺🇸
1237.25.10508 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
🇧🇪1237.25.32002 Boehringer Ingelheim Investigational Site, Turnhout, Belgium
🇧🇪1237.25.32004 Boehringer Ingelheim Investigational Site, Brussels, Belgium
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
- Conditions
- Interventions
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1137
- Registration Number
- NCT01696058
- Locations
- 🇺🇸
1222.52.02068 Boehringer Ingelheim Investigational Site, Chesterfield, Missouri, United States
🇺🇸1222.52.02035 Boehringer Ingelheim Investigational Site, Henderson, Nevada, United States
🇺🇸1222.52.02091 Boehringer Ingelheim Investigational Site, Syracuse, New York, United States
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
- Conditions
- Interventions
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1134
- Registration Number
- NCT01694771
- Locations
- 🇺🇸
1222.51.01079 Boehringer Ingelheim Investigational Site, Tamarac, Florida, United States
🇺🇸1222.51.01076 Boehringer Ingelheim Investigational Site, Austell, Georgia, United States
🇺🇸1222.51.01041 Boehringer Ingelheim Investigational Site, San Diego, California, United States
Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2012-03-21
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 219
- Registration Number
- NCT01559116
- Locations
- 🇧🇪
1237.20.32201 Boehringer Ingelheim Investigational Site, Gent, Belgium
🇳🇱1237.20.31204 Boehringer Ingelheim Investigational Site, Hengelo, Netherlands
🇭🇺1237.20.36201 Boehringer Ingelheim Investigational Site, Szarvas, Hungary
Japan Long-term Safety for Tiotropium Plus Olodaterol
- Conditions
- Interventions
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 122
- Registration Number
- NCT01536262
- Locations
- 🇯🇵
1237.22.81028 Boehringer Ingelheim Investigational Site, Koriyama, Fukushima, Japan
🇯🇵1237.22.81019 Boehringer Ingelheim Investigational Site, Koto-ku,Tokyo, Japan
🇯🇵1237.22.81010 Boehringer Ingelheim Investigational Site, Takatsuki, Osaka, Japan
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 295
- Registration Number
- NCT01533922
- Locations
- 🇺🇸
1237.13.01307 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States
🇺🇸1237.13.01305 Boehringer Ingelheim Investigational Site, Easley, South Carolina, United States
🇦🇹1237.13.43303 Boehringer Ingelheim Investigational Site, Linz, Austria
Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.
- Conditions
- Interventions
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2015-09-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 291
- Registration Number
- NCT01533935
- Locations
- 🇨🇦
1237.14.11404 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
🇦🇹1237.14.43402 Boehringer Ingelheim Investigational Site, Grieskirchen, Austria
🇦🇹1237.14.43401 Boehringer Ingelheim Investigational Site, Neumarkt am Wallersee, Austria
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2539
- Registration Number
- NCT01431287
- Locations
- 🇸🇰
1237.6.42106 Boehringer Ingelheim Investigational Site, Zilina, Slovakia
🇿🇦1237.6.27002 Boehringer Ingelheim Investigational Site, Bellville, South Africa
🇺🇸1237.6.01129 Boehringer Ingelheim Investigational Site, Henderson, Nevada, United States
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2624
- Registration Number
- NCT01431274
- Locations
- 🇺🇸
1237.5.01028 Boehringer Ingelheim Investigational Site, Columbia, Maryland, United States
🇨🇿1237.5.42005 Boehringer Ingelheim Investigational Site, Rokycany, Czech Republic
🇫🇮1237.5.35802 Boehringer Ingelheim Investigational Site, Turku, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.